To conclude... | INSM Message Board Posts

Insmed Incorporated

  INSM website

INSM   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  46880 of 48843  at  7/19/2019 7:29:13 PM  by

jsblvbjb


Strong Buy

To conclude...

Duration of treatment
o Patients that culture convert
 Have always seen recurrence in NTM MAC patients
 Patients get better with treatment regimens; then once they
stop treatment, the disease comes back for a period of time
 He thinks it would be useful to treat patients with Arikayce
once a week or one week every month to prevent the
disease from coming back after culture conversion. The
reason for this is patients will still have the scarring of the
lungs, making them susceptible to recurrence. There is no
such thing as a ‘cure’ of NTM MAC
 Coughing blood is usually the first symptom to go away
 For patients that do see culture conversion, he expects they will be
on treatment a total of 12-18 months
Patients that do not culture convert
 As long as they are not having side effects, he will keep using
Arikayce (even if not culture converting; he thinks patients will still
see small benefits)
 He is hoping the company releases data on chronic
treatment
 He does not expect payors will push back on chronic treatment


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 238
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
46882 Re: To conclude... justarook04 0 7/20/2019 7:38:21 AM






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...